BT Investment Management Ltd bought a new position in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 108,322 shares of the biopharmaceutical company’s stock, valued at approximately $6,036,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Trust Advisors LP raised its position in shares of Bristol-Myers Squibb by 10.7% in the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares during the period. Toronto Dominion Bank raised its position in shares of Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after buying an additional 162,884 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after buying an additional 3,833 shares during the period. Dividend Assets Capital LLC purchased a new position in shares of Bristol-Myers Squibb in the 2nd quarter worth $737,000. Finally, Quantitative Investment Management LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth $6,150,000. 69.82% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by insiders.

Several research analysts recently weighed in on the company. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group reissued a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Finally, Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a research report on Thursday, September 28th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $64.93.

Shares of Bristol-Myers Squibb Company (BMY) opened at $62.02 on Wednesday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The stock has a market capitalization of $102,244.66, a PE ratio of 21.10, a PEG ratio of 2.37 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the previous year, the firm posted $0.77 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/bt-investment-management-ltd-buys-shares-of-108322-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.